Preformulation studies on Imexon

Drug Development and Industrial Pharmacy

Volumn 32, Issue 6, 2006, Pages 687-697

  Kuehl, P J ^a   Hoye, W L ^a   Myrdal, P B ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

General acid base catalysis; Imexon; pH stability; Preformulation studies; Solubility

Indexed keywords

AZIRIDINE; BUFFER; HYDROGEN PEROXIDE; IMEXON; SODIUM CHLORIDE;

AQUEOUS SOLUTION; ARTICLE; DEGRADATION KINETICS; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG STABILITY; IONIC STRENGTH; MELTING POINT; PH; PREFORMULATION; TEMPERATURE;

ANTINEOPLASTIC AGENTS; BUFFERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLIZATION; DEUTERIUM OXIDE; DRUG STABILITY; HEXANONES; HYDROGEN PEROXIDE; HYDROGEN-ION CONCENTRATION; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; OSMOLAR CONCENTRATION; SODIUM CHLORIDE; SOLUBILITY; SOLVENTS; TEMPERATURE;

EID: 33746845625     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040600599830     Document Type: Article

References (17)

1. Anderson, B. D., Wygant, M. B., Xiang, T., Waugh, W. A., & Stella. V. J. (1988) Preformulation solubility and kinetic studies of 2′,3′- dideoxypurine nucleosides: potential anti-AIDS agents. Int. J. Pharm., 45, 27-37.
2. Carstensen, J. T., & Rhodes, C. T. (2000) Solution Kinetics. Drug Stability, 3rd Ed. New York: Marcel Dekker Inc., 21-27.
3. ClogP for Windows, Version 4.0, 1995-1999 Biobyte Corp.
4. Den Brok, M. W. J., Nuijen, B., Hillebrand, M. J. X., Lutz, C., Opitz, H., & Beijnen, J. H. (2005a) LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products. J. Pharm. Biomed., 38, 686-694.
5. Den Brok, M. W. J., Nuijen, B., Lutz, C., Opitz, H., & Beijnen, J. H. (2005b) Pharmaceutical development of a lyophilized dosage form for the investigational anticancer agent imexon using dimethyl sulfoxide as a solubilizing and stabilizing agent. J. Pharm. Sci., 94 (5), 1101-1114.
6. Dvorakova, K., Payne, C. M., Tome, M. E., Briehl, M. M., McClure, T., & Dorr, R. T. (2000) Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent Imexon. Biochem. Pharmacol., 60, 749-758.
7. Dvorakova, K., Payne, C. M., Tome, M. E., Briehl, M. M., Vasquez, M. A., Waltmire, C. N., Coon, A., & Dorr, R. T. (2002) Molecular and cellular characterization of Imexon-resistant RPMI8226/I Myeloma Cells. Mole. Cancer Ther., 1, 185-195.
8. Dvorakova, K., Waltmire, C. N., Payne, C. M., Tome, M. E., Briehl, M. M., & Dorr, R. T. (2001) Induction of mitochondrial changers in myeloma cells by Imexon. Neoplasia, 97 (11), 3544-3551.
9. Fubara, J. O., & Notari, R. E. (1998) A Kinetic Oxymoron: Concentration-Dependent First-order rate constants for hydrolysis of Ceftazidime. J. Pharm. Sci., 87(1), 53-58.
10. Gribbon, P., & Sewing, A. (2005) High-throughput drug discovery: what can we expect from HTS? Drug Discovery Today, 10 (1), 17-22
11. Iyengar, B. S., Dorr, R. T., Alberts, D. S., Hersh, E. M., Salmon, S. E., & Remers, W. A. (1999) Novel antitumor 2-Cyanoaziridine-1-carboxamides. J. Med. Chem., 42, 510-514.
12. Iyengar, B. S., Dorr, R. T., & Remers, W. A. (2004) Chemical basis for the biological activity of Imexon and related Cyanaziridines. J. Med. Chem., 47, 218-223.
13. Martin, A., Swarbrick, J., & Cammarata, A. (1983) Solubility and distribution phenomena. Physical Pharmacy, 3rd Ed.; Philadelphia: Lea & Febiger.
14. Ni, N., Sanghvi, T., & Yalkowsky, S. H. (2002) Stabilization and preformulation of anticancer drug-SarCNU. Int. J. Pharm., 249, 257-264.
15. Waterman, K. C., Adami, R. C. (2005) Accelerated aging: prediction of chemical stability of pharmaceuticals. Int. J. Pharm., 293, 101-125.
16. Yalkowsky, S. H. (1999) Solubillization by pH control. In Solubility and Solubilization in Aqueous Media. New York: Oxford University Press.
17. Zhu, H., Meserve, K., & Floyd, E. (2002) Preforumlation Studies for an ultrashort-acting neuromuscular blocking agent GW280430A. I. Buffer and cosolvent effects on the solution stability. Drug Dev. Int. Pharm., 28(2), 135-142.